대한약학회:학술대회논문집 (Proceedings of the PSK Conference)
- 대한약학회 2003년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2-2
- /
- Pages.133.2-134
- /
- 2003
Nano-particle encapsulated doxorubicin as an anti-cancer chemotherapeutic agent: effect on the systemic immune response I
- Lee, Hyun-Ah (The Cancer Center, Samsung Medical Center, Sunkyunkwan University) ;
- Kim, Eui-Jin (School of Medicine, Div. Hematology/Oncology, Samsung Medical Center, Sunkyunkwan University) ;
- Yu, Jeong-Jun (School of Medicine, Dept. Medical Engineering, Samsung Medical Center, Sunkyunkwan University) ;
- Shu, Soo-Won (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
- Ko, Young-Hyeh (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
- Baek, So-Young (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
- Park, Jin-Hee (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University) ;
- Lee, Hong-Gi (School of Medicine, Dept. Pathology, Samsung Medical Center, Sunkyunkwan University)
- 발행 : 2003.10.01
초록
The major hurdle of conventional chemotherapeutics is the toxicity to normal tissue. The possible therapeutic advantage(s) of nano-particle encapsulated chemotherapeutics (nano-molecules) may be the enhanced permeability and retention (EPR) effect. Nano-molecules with increase volume may incorporated into the tumor tissue selectively, which is composed of rather sparse structure. EPR effect may cause of increased effectiveness with lower tixicity to normal tissue of nano-chemotherapeutics. (omitted)
키워드